From Sangamo, With a Lock on Genetic Switch Technology, Seeks to Morph Into Drugmaker:

lanphier

lanphier—

Edward Lanphier is CEO of Sangamo Biosciences

Underwriters and Partners

Xconomy Insight

Sponsored · Whitepaper
Navigating Challenges & Advancing Clinical Development: A Toolkit for Emerging Biotechs
How incorporating more virtual/hybrid trials and decentralized research into clinical development can better integrate healthcare into patients’ real lives and accelerate approval of new medications.
Medpace

Xconomy Insight · Special Report
Biotech Startups: How to Succeed in a COVID-19 World
Industry experts explain what it takes to launch a new biotech company

Sponsored · Whitepaper
Decentralized Clinical Trials: The Call for a New Paradigm
Virtual/hybrid trials and decentralized research can better integrate healthcare into patients’ lives and accelerate approval of new medications
PRA Health Sciences

Xconomy on Demand

We offer a number of ways to subscribe for free!